Treatment of Infectious Mononucleosis
Treatment for infectious mononucleosis is primarily supportive, with rest and symptom management as the mainstay of therapy. 1, 2
Core Management Principles
Supportive Care (Primary Treatment)
The foundation of treatment consists of:
- Activity restriction: Patients must avoid contact sports and strenuous exercise for 8 weeks from symptom onset or while splenomegaly persists 1
- Rest as tolerated: Reduction of activity and bed rest based on symptom severity 1
- Symptom relief: Analgesics and antipyretics for fever and pharyngitis 2
What NOT to Do
Routine use of antivirals and corticosteroids is NOT recommended 2. This is critical because:
- Acyclovir does not ameliorate the course of infectious mononucleosis in otherwise healthy individuals 3
- Antivirals have no proven benefit in uncomplicated cases 4
- Steroids show insufficient evidence for efficacy in symptom control 5
When to Consider Specific Interventions
Corticosteroids (Limited Indications Only)
Steroids may be considered only for:
Important caveat: Benefits must clearly outweigh risks, as adverse events including respiratory distress and acute diabetes onset have been reported 5. The evidence shows no sustained benefit for sore throat relief beyond 12 hours 5.
Immunosuppressed Patients
For patients on immunomodulator therapy (e.g., IBD patients on thiopurines):
- Discontinue or reduce immunosuppressive therapy if possible during active infection 3
- In severe primary EBV infection, consider antiviral therapy with ganciclovir or foscarnet (more potent than acyclovir for replicative infection, though more toxic) 3
- Seek specialist consultation for management 3
Monitoring for Complications
Splenic Rupture Prevention
Splenic rupture occurs in 0.1-0.5% of cases and is the most feared complication 1:
- Splenomegaly occurs in approximately 50% of patients 1
- The 8-week activity restriction is specifically designed to prevent this life-threatening complication
- Patients should be counseled about avoiding abdominal trauma
Clinical Assessment Parameters
Monitor for:
- Peripheral blood findings: Leukocytosis with >50% lymphocytes and >10% atypical lymphocytes 1
- Hepatomegaly: Occurs in ~10% of cases; elevated liver enzymes increase suspicion for IM 2
- Periorbital/palpebral edema: Present in one-third of patients 1
Diagnostic Confirmation
When diagnosis is uncertain:
- Heterophile antibody (monospot) test: 87% sensitivity, 91% specificity 2
- If negative but clinical suspicion high: EBV viral capsid antigen (VCA) antibody testing (IgM with or without IgG in absence of EBNA indicates recent primary infection) 6
- False-negative monospot results common in children <5 years and during first week of illness 2
Common Pitfalls to Avoid
- Do not prescribe antibiotics empirically: 82.6% of hospitalized IM patients received unnecessary antibiotics in one study, most commonly amoxicillin/clavulanate 7
- Do not use amoxicillin or ampicillin: These cause a characteristic rash in IM patients
- Do not allow premature return to athletics: The 8-week restriction is evidence-based for splenic rupture prevention
- Do not routinely use antivirals: Despite some suggestion they may help in complicated cases 8, there is no proven benefit 4
Expected Course
- Most patients have uneventful recovery over 2-3 weeks 5
- Fatigue may be profound but typically resolves within 3 months 1
- IM is a risk factor for chronic fatigue syndrome 1
The key message: infectious mononucleosis is generally benign and self-limited, requiring only supportive care with strict activity restriction to prevent splenic rupture. Interventions beyond supportive care should be reserved for specific severe complications only.